Multiple reports detail responses to mTOR inhibitors among tumors harboring TSC1 or TSC2 mutations [7, 10], including PEComa, not otherwise specified [11], and sporadic AML [12], though DNA sequencing was not reported. Here, TSC2 is linked to acute myeloid leukemia.